Immutep (ASX:IMM) has dosed the first patient in its TACTI-004 phase 3 trial evaluating a potential combination therapy for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.

The trial is assessing Immutep's eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with NYSE-listed Merck's Keytruda anti-PD-1 therapy and chemotherapy as first-line treatment for patients with advanced or metastatic non-small cell lung cancer, per the filing.

The study's dual primary endpoints are progression-free survival and overall survival. Results will support a potential marketing approval application.

The global trial will enroll 756 patients at more than 150 clinical sites in over 25 countries, the filing stated.